(Q38071706)

28 August 2017

1 reference

title

Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes (English)

1 reference

28 August 2017

1 reference

Jeffrey A Pfefferkorn

series ordinal

1

1 reference

28 August 2017

language of work or name

English

0 references

publication date

6 January 2013

1 reference

Expert Opinion on Drug Discovery

28 August 2017

published in

1 reference

28 August 2017

volume

8

1 reference

28 August 2017

issue

3

1 reference

28 August 2017

page(s)

319-330

1 reference

New drugs for type 2 diabetes mellitus: what is their place in therapy?

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Assessing the potential of glucokinase activators in diabetes therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Functional and molecular defects of pancreatic islets in human type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

The glucose sensor protein glucokinase is expressed in glucagon-producing alpha-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Glucokinase and molecular aspects of liver glycogen metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Molecular physiology of mammalian glucokinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

The regulatory protein of liver glucokinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: evidence for a defect in hepatic glucokinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Type 2 diabetes impairs splanchnic uptake of glucose but does not alter intestinal glucose absorption during enteral glucose feeding: additional evidence for a defect in hepatic glucokinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Evidence for decreased splanchnic glucose uptake after oral glucose administration in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Regulation of endogenous glucose production by glucose per se is impaired in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Glucokinase is the likely mediator of glucosensing in both glucose-excited and glucose-inhibited central neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Glucokinase, the pancreatic glucose sensor, is not the gut glucose sensor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

A glucose sensor role for glucokinase in anterior pituitary cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Neonatal diabetes mellitus due to complete glucokinase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Familial hyperinsulinism caused by an activating glucokinase mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Glucokinase-activating GCKR polymorphisms increase plasma levels of triglycerides and free fatty acids, but do not elevate cardiovascular risk in the Ludwigshafen Risk and Cardiovascular Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Allosteric activators of glucokinase: potential role in diabetes therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Glucokinase activators in diabetes management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Novel glucokinase activators: a patent review (2008 - 2010).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

21 January 2018

Glucokinase activators

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Restoration of hepatic glucokinase expression corrects hepatic glucose flux and normalizes plasma glucose in zucker diabetic fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Transporters as a determinant of drug clearance and tissue distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Impact of drug transporter studies on drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

The expression and function of organic anion transporting polypeptides in normal tissues and in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Defect in glucokinase translocation in Zucker diabetic fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Modelling and PBPK simulation in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Molecular imaging in drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Membrane transporters in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: A bench-to-bedside case study on tissue selective drug distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.748744

10.1517/17460441.2013.748744

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference